For every seventy people worldwide who go blind from corneal disease and need a transplant, sixty-nine will never get one. That ratio—stark enough to merit a double-take—has held stubbornly constant for years, and it's the business case behind BioLattice Ophthalmics, a Philadelphia startup that just closed an oversubscribed $1.25 million pre-seed round.
The funding, announced in December 2024, backs the company's work on CorneaClear, an engineered corneal implant designed to survive at room temperature and replace the cadaveric tissue that currently dominates the transplant field. It's a technical gamble on whether lab-grown biology can solve a logistics nightmare: the world performs somewhere between 185,000 and 200,000 corneal transplants annually, yet an estimated 13 million people sit on waiting lists. The math doesn't add up, and it hasn't for a long time.
That one-in-seventy figure comes from a 2016 global survey published in JAMA Ophthalmology, later cited by the WHO. The gap reflects not just scarcity but infrastructure—donor tissue requires specialized cold chains, processing facilities, and distribution networks that much of the world simply lacks. Corneal blindness strikes roughly two million new patients each year. Most will never see a donor cornea.
Why Tissue Doesn't Scale
The supply crunch isn't news to ophthalmologists. Donor corneas need careful handling, limited shelf life, and a regulatory framework that varies wildly across borders. BioLattice's pitch is straightforward: engineer a product that works with existing surgical techniques—specifically, penetrating keratoplasty, the standard full-thickness transplant procedure—but eliminate the logistical headaches. Room-temperature stability means no cold storage. Standardized manufacturing means predictable availability.
Whether that pitch translates to clinical reality is the open question. The company has been methodical about de-risking: it secured a $274,000 NSF SBIR Phase I grant running from late 2023 through early 2025, and pulled in over $100,000 from various pitch competitions. An $80,000 award from The Enterprise Center's diversity-focused competition came through in 2023; a regional Startup World Cup win reportedly brought in another $20,000 last summer, though precise timing of some awards remains difficult to pin down publicly.
On the regulatory front, BioLattice got confirmation from the FDA that CorneaClear qualifies as a medical device following a pre-RFD submission. A pre-submission meeting was scheduled for November 2025. The company also filed an international patent application through the PCT system in mid-2025, a standard move for startups eyeing global markets.
Academic collaborations round out the picture. BioLattice has worked with Wills Eye Hospital, Thomas Jefferson University, and Lehigh University on preclinical development. Early this year, Wills Eye reportedly awarded a $20,000 grant to Dr. Zeba A. Syed for a joint evaluation of the artificial cornea in penetrating keratoplasty settings—though the timing and scope of these partnerships can shift as research progresses.
A Founder Steps Aside
Leadership transitions are common in early-stage biotech, where scientific vision and operational execution require different skill sets. BioLattice went through one this past October: Linda Alunkal, who holds an MBA from Temple and a chemical engineering background from Penn State, moved up from COO to CEO. Founder Amelia Zellander—who earned a BS from the University of Pennsylvania, an MS in Biotechnology from Johns Hopkins, and a PhD in Bioengineering from the University of Illinois Chicago in 2013—shifted to Chief Scientific Officer, a role that keeps her close to the lab bench where CorneaClear is taking shape.
It's the kind of reshuffle that signals maturation, perhaps. Or pragmatism. The company is opening a $2 million seed round, with funds earmarked for an FDA Investigational Device Exemption (IDE) submission and the clinical development work that follows. BioLattice presented at the IndieBio New York Investor Showcase earlier this year, framing its prototype as a direct challenger to the cadaveric tissue model and the handful of specialized artificial devices already on the market.
The pre-seed backers include IndieBio/SOSV, HiveBio, and Life Sciences Greenhouse Investments, supplemented by state and federal grants. BioLattice has operated out of 2929 Arch Street in Philadelphia since its 2014 founding, with a team that numbers fewer than ten people—a lean structure typical of pre-revenue biotech companies navigating the long road to regulatory approval.
The market opportunity, at least on paper, is enormous. But so are the barriers. Clinical trials for medical devices targeting the eye are expensive and slow. Manufacturing scale-up for engineered tissue involves challenges that don't apply to software or consumer hardware. And even if CorneaClear proves safe and effective, reimbursement structures and surgeon adoption patterns will determine whether it ever reaches those 13 million people on waiting lists.
Still, the one-in-seventy ratio lingers. It's the kind of statistic that makes for compelling pitch decks—and, if the science holds, a case study in whether bioengineering can solve problems that donation networks have struggled with for decades.
